Overview
Servier Polska Services is involved in the development and production of original pharmaceuticals, focusing on three therapeutic areas: cardiometabolism, oncology, and neurology. The company has received European Commission approval for worasydenib, a targeted molecular therapy for patients with glioma. Additionally, 98% of the active substances in Servier's original medications are manufactured within the European Union.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Servier Polska joins the "Inclusive in Employment" Coalition
SEE YOU TOMORROW – ordinary words gaining new meaning
Servier Polska Office Work from 01.07.2026 to 31.08.2026
20 Years of the “Crystal Pens” Contest - We Know the Winners of the Jubilee Edition of the National Journalists' Contest
Hypertension Quietly Steals the Future. Time to Regain Control
Servier-Turn Off Cancer Campaign “Go Deeper INTO IT” Awarded INNOVATOR ESG 2025
Industry
Bank accounts
Registered as a VAT taxpayer on 2002-03-29. Active
02 1840 0007 2212 3880 0800 1719
17 1030 1335 0000 0008 2206 2500- 27 1840 0007 2212 3880 0819 0710
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
981 tenders recorded as contractor: 186 national ($6,703,804) and 795 EU ($3,143,662,681).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Oct 2, 2026 | Dostawa leków programowych, onkologicznych, płynów infuzyjnych, erytropoetyny oraz kontrastów | —— | Wojewódzki Szpital Specjalistyczny Nr 4 w Bytomiu | |
| Oct 1, 2026 | Dostawa LEKÓW, produktów medycznych i farmaceutycznych dla Samodzielnego Publicznego Zakładu Opieki Zdrowotnej w Kępnie | —— | Samodzielny Publiczny Zakład Opieki Zdrowotnej w Kępnie | |
| Sep 30, 2026 | Dostawa produktów leczniczych różnych dla SPZOZ w Sanoku | —— | Samodzielny Publiczny Zespół Opieki Zdrowotnej w Sanoku |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
Each member of the management board has the right to represent the company individually.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Arts Et Techniques Du Progres S.a.s. | 15,050 | $4,065,370.07 | 94.9527% |
Others | 800 | $216,099.41 | 5.0473% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Olivier Jacques, Gerard Laureau (69)  | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Przedsiębiorstwo Dystrybucji Farmaceutycznej Slawexsp. z o.o. | $600,815,720.02 | slawex.com.pl | ||
| Brenntag Polskasp. z o.o. | $548,791,874.18 | brenntag.pl | ||
| Sanofisp. z o.o. | $384,123,246.36 | sanofi.pl | ||
| USP Zdrowiesp. z o.o. | $377,149,656.94 | uspzdrowie.pl | ||
| NovoS.A. | $209,522,261.96 | novo-sa.pl | ||
| Bialmedsp. z o.o. | $203,238,055.12 | bialmed.pl | ||
| LubfarmS.A. | $123,208,945.21 | lubfarm.pl | ||
| DiagnosisS.A. | $37,413,735.72 | diagnosis.pl | ||
| SymbaseS.A. | $26,081,930.68 | cfiworld.pl | ||
| Synkmedsp. z o.o. | $20,634,200.47 | synkmed.pl |
Change history
| Date | Event | |
|---|---|---|
| 2022-10-19 | Address change (Ul. Jana Kazimierza 10, 01-248, Warszawa → Ul. Burakowska 14, 01-066, Warszawa) | |
| 2015-06-01 | Address change (Annopol 6b, 03-236, Warszawa → Ul. Jana Kazimierza 10, 01-248, Warszawa) | |
| 2009-09-25 | Share capital change (15,050,000.00 PLN → 15,850,000.00 PLN) | |
| 2005-01-10 | Share capital change (50,000.00 PLN → 15,050,000.00 PLN) | |
| 2004-10-12 | Address change (Sienna 75, 00-833, Warszawa → Annopol 6b, 03-236, Warszawa) |
FAQ
Last updated: 2026-03-25